Senti Biosciences Inc. (NASDAQ: SNTI) announced updated clinical data from its ongoing Phase 1 trial of SENTI-202, an experimental cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE